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Abstract 
Objective
Guillain-Barré Syndrome (GBS) is an acute inflammatory 
polyneuropathy characterized by a rapid progressive symmetric 
weakness. The GBS is the most common cause of acute flaccid 
paralysis (AFP) in most parts of the world. This study was carried out 
to investigate the epidemiological features of GBS in Iranian children. 
Materials & Methods
 The data were extracted using the AFP surveillance system that is 
a national screening program to detect all cases of AFP aged 0-15 
years around the country. National Population Statistics data and AFP 
demographic data during 2008-2013 intervals were obtained from the 
relevant authorities in the Ministry of Health in Iran. The GBS cases 
were then extracted from the aforementioned database. The Chi-
square test and Fisher’s exact test were used for statistical analysis.
Results 
A total of 1884 cases of GBS were identified in the study period, and 
the average annual incidence rate was 1.72 per 100,000 individuals. 
The highest incidence rate was within the range of 0-5 years. There 
was no statistically significant relationship between the incidence of 
GBS and the season in the whole country.
Conclusion
 High costs of GBS  treatment,  morbidity and occasional mortality, 
and number of new cases, which is estimated to be approximately 
300 individuals per year, need the particular attention of the health 
system.
28
Epidemiology of Guillain-Barré Syndrome in Iranian Children Aged 0-15 Years (2008-2013)
Iran J Child Neurol. Autumn 2021 Vol. 15 No. 4
of Epidemiology, Faculty of Health, 
Shahid Beheshti University of Medical 
Sciences, Tehran, Iran. 
6. Pediatrics Infectious Research 
Center, Shahid Beheshti University of 
Medical Sciences, Chairman of National 
Certification Committee for Polio 
Eradication, Tehran, Iran. 
7. Student Research Committee, School 
of Medicine, Kerman University of 
Medical Sciences, Kerman, Iran
Corresponding Author
Nejad Biglari H.MD 
Assistant Professor of Pediatrics, 






The GBS is the most common cause of subacute 
and acute flaccid paralysis (AFP) in neonates and 
children. All age groups can be affected by GBS, 
and it seems that adults are more susceptible than 
children. The worldwide incidence of GBS for all 
ages has been estimated to be within the range 
of 0.4-2.4 per 100,000 individuals. The annual 
incidence in children seems to be lower estimated 
to be within the range of 0.4-1.3 per 100,000 
individuals. 
The prognosis of GBS in children is generally 
excellent that is quite different from adults who 
have higher morbidity and mortality (4). There 
is no significant difference in GBS incidence 
among seasons, although a limited number of 
studies suggested a seasonal variation (1). With 
this background in mind, the current study aimed 
to determine the annual incidence of GBS in 
children, analyze morbidity and mortality rates, 
and compare these rates according to age, gender, 
and geographical and seasonal variations.
Materials & Methods
This cross-sectional study was conducted on 
Iranian children under 15 years of age with GBS 
within 2008 and 2013. Patients’ information was 
obtained using the database extracted from the 
AFP surveillance system, which is designed by 
the World Health Organization (WHO) to screen 
children aged 0-15 years with AFP in polio-free 
countries with a high risk of imported polio. 
This program is implemented by the Preventable 




Guillain-Barré Syndrome (GBS) is an acute 
acquired peripheral neuropathy characterized by 
rapidly developing motor weakness (1). The GBS 
has an autoimmune etiology and in the two-third of 
cases is triggered by respiratory or gastrointestinal 
infections (2, 3). The pathology is an inflammatory 
disorder affecting the myelin sheath and the axon 
leading to diffuse demyelination and axonal 
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Diseases Department of the Ministry of Health in 
Iran and is annually evaluated and approved by the 
WHO. 
These AFP cases are classified in each province by 
regional AFP committees (composed of infection, 
epidemiologist, and neurologist experts). Then, 
GBS patients were separated from other AFP cases 
and analyzed. The GBS children information sheet 
included patients’ code, name, age, gender, date of 
birth, date of paralysis, early-onset symptoms of 
the disease, a remnant of paralysis after 60 days 
of occurrence, and home address (within 2008 and 
2013). 
Based on the 2008 census and demographic 
estimates, the populations of each province 
and the whole country were obtained from the 
Statistics National Center for the years 2008-2013. 
Total Iranian populations were 70,495,882 and 
75,149,669 individuals after the 2006 and 2011 
censuses, respectively. The numbers of children 
under 15 years of age were 17,681,629 and 
17,561,778 in 2006 and 2011, respectively. 
The data were collected from information sheets 
and entered in SPSS software (version 20) and 
analyzed. Mean and standard deviation and relative 
and absolute frequency were used to analyze 
quantitative and qualitative variables, respectively. 
Moreover, the Chi-square test and Fisher’s exact 
test were performed to investigate the association 
between demographic and epidemiological 
factors with GBS. A p-value of less than 0.05 was 
considered statistically significant. 
Results
Within 2008 and 2013, 1884 cases of GBS were 
diagnosed, including 333 cases in 2008, 309 cases 
in 2009, 322 cases in 2010, 307 cases in 2011, 
321 cases in 2012, and 292 cases in 2013 with 
the mean age values of 4.96±3.54, 5.60±3.96, 
5.47±3.77, 5.66±3.97, 5.25±3.54, and 6.05±3.79 
years, respectively. Altogether, 1061 (56.3%) 
and 823 (43.7%) children were male and female, 
respectively. Furthermore, there was no statistically 
significant difference between the genders of 
patients in each year (P=0.587).
The mean incidence rate of GBS during the 
study period (2008-2013) was 1.72 per 100,000 
individuals in children under 15 years of age. 
The highest (1.93%) and lowest (1.65%) 
incidence rates were reported in 2012 and 2008, 
respectively (Figure 1). Overall, during the study, 
the investigation of the age distribution of cases 
showed 4% of cases under 1 year, 50% of cases 
within 1-5 years, 30% of cases within 5-10 years, 
and 16% of cases within 10-15 years of age.
In this study, 579 (30.7%) cases had a fever during 
the last week before paralysis. Residual motor 
deficit after 60 days of paralysis onset was in the 
order of 31.8% in 2008, 34.4% in 2009, 35.1% in 
2010, 34.0% in 2011, 27.1% in 2012, and 22.7% 
in 2013. The rest of the patients, excluding death 
cases, were recovered before 60 days. Residual 
paralysis or weakness (at least one muscle group at 
≤ grade 6 level) ranged from steppage gait to non-
ambulatory state (i.e., bed or chair bound). Grade 6 
is the ability to move a muscle against gravity with 
minimal resistance to force.
Out of 1884 cases, 29 children (1.5%) with GBS 
died. The results also showed that there was a 
significant difference between the mortality rate 
and age group (P=0.024) with maximum mortality 
in children under 5 years of age; however, there 
was no significant difference between the mortality 
rate and the gender of children with GBS (P=0.451; 
Table 1)
Figure 2 shows the distribution of incidence rates 
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of GBS in different Iranian provinces. According 
to Figure 2, Semnan (3.7 in 100,000) and Ilam 
(2.8 in 100,000) have the highest incidence rates 
of GBS, and Bushehr (0.7 in 100,000) and Gilan 
(0.8 in 100,000) have the lowest incidence rates of 
GBS.
During 6 years of study (2008-2013), the incidence 
rates of GBS were 1.6 and 1.9 in girls and boys 
per 100,000 children under 15 years of age, 
Table 1. Age Distribution and Gender Influence on Guillain-Barré Syndrome Outcomes in Children Under 15 Years of Age 
Outcome 
n (%)




































Figure 3 shows seasonal variability of GBS 
incidence in children illustrating the percentage 
of patients who were affected during each season 
based on the study years. The incidence rate of GBS 
according to the season during 2008-2013 showed 
no significant difference among the seasons in 
different years (P=0.157). 
Fig 1. Guillain-Barre syndrome incidence in children under 15 years old during 2008-13
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Fig 2. the distribution incidence rate of Guillain Barre Syndrome per 100,000 populations of children less than 15 years old in each province of Iran 
(2008-2013)
Fig 3. Seasonal variability of GBS incidence in children less than 15 years (2008-2013)
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Discussion
This descriptive cross-sectional retrospective study 
was based on the data from the AFP surveillance 
system in Iranian children aged 0-15 years with 
GBS during 2008-2013 intervals. Historically, 
the overall incidence rate of GBS at all ages was 
within the range of 0.4/100,000 in Sardinia, Italy, 
(5) to 4/100,000 in Larimer County, Colorado (6). 
The incidence of GBS in children (age range: 0-15 
years) seems to be lower than that in adults with 
a range of 0.34-1.34/100,000 per year (1). The 
highest rate was reported in adult patients above 
75 years of age (4.5/100,000) (1).
With 1884 cases of GBS, the present study reported 
the largest number of patients aged 0-15 years from 
one country (1), preceded by olive et al. reporting 
1678 affected children from Brazil (7). The 
prospective method of studying GBS incidence 
is considered to be more reliable, compared to 
the retrospective one (1). Nevertheless, in the 
current retrospective study, each case with AFP 
was reviewed by an expert committee and the 
diagnosis of GBS was confirmed, minimizing the 
risk of overestimation of GBS reports. Regarding 
two national censuses in 2006 and 2011, the total 
population of the present study is accurate. 
The case definition in the current study was 
based on AFP patients reported from all around 
the country. The GBS cases were identified after 
further clinical and electrophysiological studies; 
this means that the major manifestation was a 
motor deficit. In addition, theoretically, this study 
could have missed rare cases of acute sensory 
neuropathy with only sensory nerves or roots 
involvement and atypical cases, such as Miller 
Fisher syndrome that is not presented with flaccid 
paralysis. However, this fact can have a negligible 
effect since these atypical cases are rare (less than 
5%), and they can only change the incidence of 
GBS by approximately 0.1 per 100.000 individuals 
(8, 9).
A recent study from Bangladesh showed an 
incidence rate of 1.5 to 2.5/100,000 individuals 
per year in children under 15 years of age (10), 
indicating a probable increase in childhood GBS 
incidence. With a mean incidence of 1.72 per 
100,000 individuals, the present study supports the 
aforementioned hypothesis. This presumed rise in 
incidence could be explained by a better diagnosis 
of the disease by physicians, a better national 
registry network, and the emergence of many new 
environmental factors (i.e., chemical, physical, and 
microbiological) that can modulate the immune 
system. However, researchers should wait for 
performing extensive surveys from other countries 
to document the possible rise in GBS incidence.
In a 6-year cross-sectional study (2001-2006) 
in East Azerbaijan, Iran, Barzegar et al. reported 
an incidence of GBS, in a 0-to-15-year interval, 
ranging from 0.16 to 4 per 100.000 individuals (11). 
There was a peak incidence in 2003 (probably after 
a campylobacter outbreak in the northwest of Iran) 
with a similar peak in GBS mortality during this 
year). All studies showed a male predominance in 
GBS which is unusual in a presumed autoimmune 
disease. The male: female GBS ratios in all ages 
were reported as 1.25:1 in the UK (3), 1.7:1 in 
Western Balkans countries, and 1.1:1 in Spain 
(12). The male to female ratio was 1.27:1 in the 
present cohort that is almost similar to those of 
other countries in all age groups. 
Childhood GBS generally has a good prognosis in 
contrast to adult GBS with higher morbidity and 
mortality (4). The mortality rate in childhood GBS 
was 0% in Toronto, Canada (13); nonetheless, 
there was a mortality rate of 1.5% which could be 
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explained by delay in patients’ referral to tertiary 
hospitals when sophisticated respiratory and 
intensive care unit care was available. During an 
11-year study period (1989 -1999) in Honduras, the 
mortality rate in childhood GBS was 7.3%. Most 
of the mortality cases of the present study occurred 
in children under 5 years of age. The reason for this 
age distribution is the non-specificity of symptoms 
in early childhood, delay in the correct diagnosis, 
and vulnerability of young children to respiratory 
failure and autonomic dysfunction (14).
Residual motor deficit after 60 days of paralysis 
onset annually ranged from 22.7% to 35.1%. In 
this study, there was no longer follow-up for the 
patients. Vajsar J et al. reported a persistently 
decreased muscle power (with at least one muscle 
group having movement against gravity but with 
minimal resistance against a force) in 23% of 
children with GBS during an average 5-year 
follow-up in Toronto (13).
No significant seasonal variation in GBS incidence 
was reported in other studies (15-18), although a 
Brazilian study showed outbreaks in spring and 
summer (19) and another study in Netherland 
showed an increase in incidence in winter and June 
(20). Xiujuan Wu et al. reported a higher incidence 
of childhood GBS in summer (21). Despite 
different climates in Iran, there was no significant 
difference in the seasonal incidence of GBS in the 
patients of this study.
The age distribution of GBS is bimodal according to 
some studies, with peaks occurring in young adults 
and the elderly (2, 22, 23). In the current study, 
50% of all GBS cases were within the age range of 
1-5 years, for which there was no explanation and 
no similar results were obtained in other studies.
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